激素替代治疗与心血管风险升高相关:英国生物样本库队列中生殖因素与动脉粥样硬化性心血管疾病结局的综合分析
基于英国生物样本库170250名40–69岁女性的前瞻性队列(2006–2024),曾使用激素替代治疗(HRT)与动脉粥样硬化性心血管疾病(ASCVD)风险升高相关(校正HR 1.13,95%CI 1.08–1.18),主要来自缺血性卒中;风险因生殖特征和年龄而异,围绝经期最为显著(HR 1.28,95%CI 1.12–1.46)。
要点
- 曾使用HRT与ASCVD风险升高相关(校正HR 1.13,95%CI 1.08–1.18,p<0.001),主要来自缺血性卒中增加。
- 围绝经期风险升高最明显(HR 1.28,95%CI 1.12–1.46),≤45岁女性使用HRT的ASCVD风险升高77%。
- 性激素、炎症标志物和血脂的中介效应均<2%,提示直接的血管机制。
核心结论
- HRT增加ASCVD风险,且风险因生殖特征不同而存在显著差异;研究结果支持基于生殖特征的心血管风险评估以指导个体化HRT处方。
研究设计与样本
- 前瞻性队列研究,分析英国生物样本库(UK Biobank)2006–2024年170250名40–69岁女性。
- 采用Cox比例风险回归模型估计ASCVD风险,按生殖特征(初潮年龄、绝经年龄、绝经状态)和年龄组(≤45、46–55、>55岁)分层。
- 进行中介分析,检验性激素、炎症标志物和血脂谱等潜在生物学通路。
- 所有分析均校正人口学因素、社会经济状况、生活方式因素和生殖史。
主要发现
- 随访期间11357名女性(6.67%)发生ASCVD。
- HRT使用者ASCVD风险升高(校正HR 1.13,95%CI 1.08–1.18,p<0.001),主要来自缺血性卒中增加。
- 风险因生殖特征而异:初潮晚风险最高(HR 1.15,95%CI 1.08–1.24),其次为绝经晚(HR 1.25,95%CI 1.01–1.54)。
- 围绝经期风险升高最明显(HR 1.28,95%CI 1.12–1.46);≤45岁女性使用HRT的ASCVD风险升高77%。
- 观察到HRT持续时间(≥5年)与ASCVD风险之间的剂量–反应关系(总体p=0.009,非线性p=0.004)。
临床怎么用
- 研究结果支持基于生殖特征的心血管风险评估以指导个体化HRT处方(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among 170,250 UK Biobank women (2006–2024), ever HRT use was associated with higher incident ASCVD risk (adjusted HR 1.13, 95% CI 1.08–1.18), largely driven by ischemic stroke. Associations were stronger in women ≤45 years and during perimenopause. Mediation via sex hormones, inflammatory markers, or lipids was minimal (<2%). Abstract Introduction The cardiovascular effects of hormone replacement therapy (HRT) remain controversial. This study investigated HRT-associated atherosclerotic cardiovascular disease (ASCVD) risk, focusing on reproductive characteristics. Material and Methods This prospective cohort study analyzed 170 250 women aged 40–69 years from UK Biobank (2006–2024). Cox proportional hazards regression models were employed to estimate ASCVD risk, with stratification by reproductive characteristics (age at menarche, age at menopause, and menopausal status) and age groups (≤45, 46–55, >55 years). Mediation analysis was conducted to examine potential biological pathways through sex hormones, inflammatory markers, and lipid profiles. All analyses were adjusted for demographic factors, socioeconomic status, lifestyle factors, and reproductive history. Results During follow-up, 11 357 women (6.67%) developed ASCVD. HRT users demonstrated elevated ASCVD risk (adjusted HR 1.13, 95% CI 1.08–1.18, p < 0.001), primarily from increased ischemic stroke. Risk varied by reproductive characteristics: late menarche showed highest risk (HR 1.15, 95% CI 1.08–1.24), followed by late menopause (HR 1.25, 95% CI 1.01–1.54). Perimenopause demonstrated the most pronounced elevation (HR 1.28, 95% CI 1.12–1.46). Women ≤45 years had 77% higher ASCVD risk with HRT use. Dose–response relationships between HRT duration (≥5 years) and ASCVD risk were observed (p overall = 0.009, p nonlinear = 0.004). Mediation analysis revealed minimal indirect effects through traditional biomarkers (<2%), suggesting direct vascular mechanisms. Conclusions HRT increases ASCVD risk with substantial variation by reproductive characteristics. Findings support reproductive profile-based cardiovascular risk assessment for personalized HRT prescribing.
引用
- Acta Obstetricia et Gynecologica Scandinavica:Elevated cardiovascular risk associated with hormone replacement therapy: A comprehensive analysis of reproductive factors and atherosclerotic cardiovascular disease outcomes in the UK Biobank cohort
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。